Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Q4 2022 Earnings Conference Call March 28, 2023 4:30 PM ET

Company Participants

Matt Steinberg - Investor Relations, FINN Partners

Scott Davis - Chief Executive Officer

Jason Jones - Chief Operating Officer

Jerome Wong - Chief Financial Officer

Conference Call Participants

Swayampakula Ramakanth - H.C. Wainwright

Operator

Greetings, and welcome to the Ekso Bionics Fourth Quarter 2022 Financial Results Conference Call.

At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] And as a reminder, this conference is being recorded.

It is now my pleasure to introduce your host, Matt Steinberg with FINN Partners. Thank you, Matt. You may begin.

Matt Steinberg

Thank you, operator, and thank you all for participating in today's call. Joining me from Ekso Bionics are Scott Davis, Chief Executive Officer; Jerome Wong, Chief Financial Officer; and Jason Jones, Chief Operating Officer.

Earlier today, Ekso Bionics released financial results for the quarter and year ended December 31, 2022. A copy of the press release is available on the company's website.

Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements within the meaning of the federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical fact should be deemed to be forward-looking statements.

All forward-looking statements, including statements regarding our business strategy, future financial or operating expectations, or our expectations of the regulatory landscape governing our products and operations are based upon management's current estimates and various assumptions. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated or implied by these forward-looking statements.

Accordingly, you should not place undue reliance on these statements. For a list and description of the risks and uncertainties associated with our businesses, please see our filings with the Securities and Exchange Commission. Ekso disclaims any obligation except as required by law to update or revise any financial or operational projections, its regulatory outlook or other forward-looking statements, whether because of new information, future events or otherwise.

This conference call contains time sensitive information and is accurate only as of the broadcast today, March 28, 2023.

I will now turn the call over to Ekso Bionics' Chief Executive Officer, Scott Davis.